WuXi and PRA canceling joint venture in China

With WuXi PharmaTech concentrating on manufacturing and PRA Health Sciences ($PRAH) developing its own global strategy, the two companies have decided to split up their China-focused joint venture. Instead, they will have an alliance but will divide their operations in the country after more than two years of collaboration. Story

Suggested Articles

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back. 

The lawmakers question Kodak's fitness for such a major pharma manufacturing deal, as well as suspicious stock transactions by company leadership.

AZ's China COVID-19 vaccine deal comes after supply agreements with the U.S., the U.K., EU and Brazil, as well as licensing pacts in India and Japan.